登录 | 注册    关注公众号  
微信公众号
搜索
 >  Beads>Spike protein >MBS-K031

SARS-CoV-2 Spike Trimer (P.1) Coupled Magnetic Beads

热销产品推荐:The Magnetic Stand (Cat.No. MB-01 & Cat.No. MB-02) can be used in conjunction with Beads.

ItemsSize (2mg)Size(5mg X 2)
Particle size2 μm2 μm
Physical appearancePowder mixturePowder mixture
Amount of Coupled Protein≈286 pmol (40 μg) SARS-CoV-2 Spike Trimer (P.1)/mg beads≈286 pmol (40 μg) SARS-CoV-2 Spike Trimer (P.1)/mg beads
Binding Capacity>242 pmol (36 μg) Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody/mg beads>242 pmol (36 μg) Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody/mg beads
FormulationPBS, pH7.4, with 10% TrehalosePBS, pH7.4, with 10% Trehalose
Reconstitution2 mL sterile deionized water (1 mg beads/mL)5 mL sterile deionized water (1 mg beads/mL)

背景(Background)

The SARS-CoV-2 Spike Trimer (P.1) Coupled Magnetic Beads is produced by coupling biotinylated SARS-CoV-2 spike trimer to streptavidin-conjugated magnetic beads. The spike proteins coupled to the beads contain 12 mutations (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F) identified in the Brazilian variant (known as P.1). The pre-coupled beads are ready to use for capturing anti-SARS-CoV-2 antibody or ACE2 protein from your sample with high specificity.

表达区间及表达系统(Source)

SARS-CoV-2 Spike Trimer (P.1) Protein is expressed from human 293 cells (HEK293). It contains AA Val 16 - Pro 1213(Accession # QHD43416.1 (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F, R683A, R685A,F817P, A892P, A899P, A942P, K986P, V987P)).

应用说明(Application)

This product is intended for immunocapture, biopanning and flow cytometry. This product is produced non-sterile.

重构方法(Reconstitution)

See Certificate of Analysis (CoA) for detailed instruction.

存储(Storage)

Upon receipt, please store the Beads at -20°C. The shelf life is 1 year at -20 °C.

Please avoid more than 3 freeze-thaw cycles once reconstitution, immediate use after reconstitution is highly recommended.

原理(Assay Principles)

Antibody Purification: 1. Resuspend the lyophilized beads by adding the buffer of choice. 2. Add analyte to the suspension, mix and incubate to enable specific binding of the beads and the target protein. 3. Magnetize beads, remove supernatant, and wash unbound protein fractions to capture target protein-bound beads. 4. Wash, magnetize the beads and collect purified target protein for use in downstream applications.

The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications.

制剂(Formulation)

Please contact us for detailed information.

Contact us for customized product form or formulation.

 

典型数据-Typical Data

Spike protein TYPICAL DATA

Immobilized 40 μg SARS-CoV-2 S protein trimer to 1mg Beads can bind the ACE2 with an EC50 of 0.14μg/mL (QC tested).

Protocol

Spike protein TYPICAL DATA

Accelerated stability test. After placing the lyophilized beads at 37°C for 7 days, binding activity between the S SARS-CoV-2 Spike Trimer (P.1) Coupled Magnetic Beads (Cat.No. MBS-K031) and anti-SARS-CoV-2 Spike S1 antibody showed little deviation from the unaccelerated sample (%RSD<5%). Data were measured on day 0, 3, 7 respectively.

Protocol

Spike protein TYPICAL DATA

Freeze-thaw stability test. After different freeze-thaw cycles, binding activity between SARS-CoV-2 Spike Trimer (P.1) Coupled Magnetic Beads (Cat.No. MBS-K031) and anti-SARS-CoV-2 Spike S1 antibody showed little deviation from the unfree-thaw sample (%RSD<5%). Three freeze-thaw cycles were performed.

Protocol

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Spike protein靶点信息
英文全称:Coronavirus spike glycoprotein
中文全称:冠状病毒刺突糖蛋白
种类:Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2)
上市药物数量:9详情
临床药物数量:71详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细
相关产品
View All Spike protein

消息提示

请输入您的联系方式,再点击提交!

确定